Novavax to get capital infusion
The same day Novavax Inc. announced it is getting a much-needed capital infusion from an Indian pharmaceutical company, the biotech reported a $36 million loss for 2008.
Novartis, the Swiss pharmaceuticals group, plans to invest $500m in Russia in the coming five years in a move to bolster its position in the market and bypass tougher regulations on imported medicines.